Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRBP NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRBPKiromic BioPharma$0.16$1.16$0.16▼$3.32$252K1.6611,347 shsN/AWINTWindtree Therapeutics$0.02+28.6%$0.02$0.01▼$1.86$810K1.62340,727 shs28,112 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRBPKiromic BioPharma0.00%0.00%0.00%0.00%-23.76%WINTWindtree Therapeutics+25.87%+25.00%-9.55%+78.22%-97.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRBPKiromic BioPharma$0.16$1.16$0.16▼$3.32$252K1.6611,347 shsN/AWINTWindtree Therapeutics$0.02+28.6%$0.02$0.01▼$1.86$810K1.62340,727 shs28,112 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRBPKiromic BioPharma0.00%0.00%0.00%0.00%-23.76%WINTWindtree Therapeutics+25.87%+25.00%-9.55%+78.22%-97.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRBPKiromic BioPharma 0.00N/AN/AN/AWINTWindtree Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/AWINTWindtree Therapeutics-$1.79M-$8.77N/AN/AN/AN/A-207.34%-50.19%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKRBPKiromic BioPharmaN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRBPKiromic BioPharmaN/A0.160.22WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRBPKiromic BioPharma10.91%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipKRBPKiromic BioPharma20.59%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableWINTWindtree Therapeutics3044.99 million3.66 millionNot OptionableKRBP and WINT HeadlinesRecent News About These CompaniesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comWindtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comWindtree Expands Global Patent Portfolio as Heart Failure Pipeline Gains MomentumNovember 20, 2025 | msn.comWindtree may receive license agreement payments for renewed development workNovember 17, 2025 | msn.comWindtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeNovember 17, 2025 | finance.yahoo.comWindtree Therapeutics announces patents allowed in Canada, MexicoNovember 14, 2025 | msn.comWindtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent EstateNovember 14, 2025 | markets.businessinsider.comWindtree Therapeutics Delays Quarterly Report FilingNovember 14, 2025 | tipranks.comWindtree Therapeutics Signs Letter of Intent with TESI for $7.5 Million Cash and Securities AgreementNovember 13, 2025 | quiverquant.comQWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comNew MarketBeat Followers Over TimeKRBP and WINT Company DescriptionsKiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Windtree Therapeutics NASDAQ:WINT$0.02 +0.00 (+28.57%) As of 06/12/2026 03:50 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
